MYnd Analytics Invited to Participate At Cavendish

The Panel Discussion Titled: Innovations in Technology Driving Mental Health Treatment

SAN DIEGO, Feb. 07, 2017 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (OTCQB:MYAN), a predictive medicine company which adds objective physical and or biometric findings to psychiatric treatment in order to reduce trial and error treatment in mental health, announced today that George Carpenter, President and CEO of MYnd Analytics, Inc., will be a panelist at the Cavendish Global Health Impact Forum panel titled, “ Innovations in Technology Driving Mental Health Treatment,” discussing the emergence of new technologies in mental health, including predictive analytic tools, which can assist physicians in reducing trial and error when prescribing medications for mental health patients.

The panel will be moderated by Dr. Henry Harbin, a Psychiatrist with over 40 years of experience in behavioral health, holding a number of senior positions in both public and private health care organizations including, being CEO of Magellan Health Services, which under his tenure was the largest managed behavioral healthcare company managing the mental health and substance abuse benefits for private employers, Medicaid and Medicare covering approximately 70 million Americans and being responsible for approximately $2 billion in annual revenues. Another panelist will be Zack Lynch, author of “The Neuro Revolution: How Brain Science Is Changing Our World”, and co-founder and General Partner of JAZZ Venture Partners, which invests in companies developing experiential technologies (i.e. XTech) to improve human performance. Mr. Lynch is also the founder and Chairman of the Neurotechnology Industry Organization, a global trade association representing companies involved in neuroscience, brain research institutes and patient advocacy groups.

About MYnd Analytics, Inc.

MYnd Analytics, Inc. ( www.myndanalytics.com ) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG).  Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.

To read more about the benefits of this patented technology for patients, physicians and payers, please visit  www.myndanalytics.com .

About Cavendish Global

The Cavendish Global is a community of 280 family offices, foundations and other impact investors who share a passion for supporting innovations and initiatives that have the potential to change the landscape of health care. The community comes together at their forums several times a year, along with select early-stage health and life science companies. Their mission is to provide the resources, connectivity and thought leadership necessary to drive paradigm-changing ideas from the lab to the marketplace. The Forums have been hosted by a number of leading institutions, including the United Nations, the New York Academy of Sciences, the University of Oxford, Scripps Research Institute, and the Cleveland Clinic and a couple hundred people attend.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond MYnd Analytics' control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to MYnd Analytics' plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions (including their use in the negative), or by discussions of future matters such as the expansion strategy with multisite physician practices; balance sheet strength and flexibility to support ongoing activities; our ability to  continue business development and M&A activity; our ability to support commercialization of the PEER product; and other statements that are not historical.  These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contact Paul Buck, CFO MYnd Analytics 949-420-4402 Work 866-867-4446 Fax PBuck@MYndAnalytics.com